PFDN4

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit's Bispecific Complement Engaging (BiCE™) platform AARHUS, Denmark, June 10, 2024 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces it will present a poster containing key data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics, which is being held in Loutraki, Ancient Corinth, Greece, on June 11-16, 2024. Details of the presentation Poster Title: BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases Presenter: Dr Nick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics The data will reveal optimization of the BiCE™ platform and show that Commit's second-generation BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies. With a novel mechanism of action, Commit's technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases. The complement system is part of the body's immune system that has previously been largely untapped for therapeutic purposes. Commit has built a novel Bispecific Complement Engaging (BiCE™) platform to arm validated antibodies and activate the complement system to selectively kill cancer cells or cells that drive autoimmune diseases. Commit's BiCE™ platform uses bispecific single domain antibodies, where one arm recognizes the complement protein C1q and the other arm recognizes a selected target, such as a cancer-specific antigen. These bispecific engagers efficiently recruit C1, leading to potent complement activation. Nick Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics, said: "We are excited to be presenting Commit's unique approach to activating complement for therapeutic purposes and to highlight the tremendous potential of our innovative BiCE™ platform to harness the immune system in a different way to tackle cancer and autoimmune disease." Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: "Having officially come out of stealth just a few weeks ago, it's great to have the opportunity now to showcase our novel BiCE™ platform to fellow complement system experts and to our peers who are developing therapeutics in the field of complement. We believe our approach represents a powerful new way of engaging the complement system to tackle a broad range of diseases." The 16th International Conference on Complement Therapeutics brings together academic and industry leaders to share new data and discuss the latest developments in therapeutic design, clinical trials, and complement-driven pathophysiology in emerging indications. About Commit Biologics Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings. About the complement system The complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defense, begins with the engagement of C1q to antibodies that coat the cell surface and ends with the activation of a cytolytic complement complex directly leading to cell lysis. However, current monoclonal antibodies developed for therapeutic purposes have structural restraints that hinder effective engagement to C1q, thus limiting complement mediated cytotoxicity and other complement mediated effector functions. This, plus the presence of natural cell bound complement inhibitors that are upregulated in cancer, and low target densities, make conventional therapeutic antibodies poor complement activators. Commit's BiCE™ technology was developed to overcome these barriers, to harness the power of the complement system and direct it towards tumor and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit's technology potentially allows for a broad therapeutic index and the development of highly effective treatments. SOURCE Commit Biologics

New York, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026”. “According to the recent research report, the demand of global C1 Inhibitors Market size & share expected to reach to USD 9,800 Million by 2026 from USD 3,300 Million in 2019, at a compound annual growth rate (CAGR) of 18.6% during the forecast period 2021 to 2026” Global C1 Inhibitors Market: Overview C1 inhibitors are a type of protease inhibitor that belongs to a protein-based ingredient called serpin. They are also called C1 esterase inhibitors; however, unlike other members of the protein tree, they contain both the domains C-terminal and N-terminal. These inhibitors basically help lower the self-consciousness of the complement system to prevent any type of damage as well as to retain the functionality. It is an FXIIa inhibitor that can help coagulate blood, produce kinins or fibrinolysis, and also activate the complement system. The rising prevalence of hereditary angioedema (HAE) diseases and the preferred mode of treatment for prophylactic-based disorders are likely to drive the growth of the market during the forecast period. Additionally, certain impactful studies have indicated that the use of C1 inhibitors will further drive the growth of the market. Furthermore, the growing awareness regarding the effectiveness of C1 inhibitors and their ability in preventing heart attacks will boost the market expansion. C1 inhibitors use as a short-term treatment for prophylactic diseases propel the demand for this product across the globe. But, a few of the reasons including misdiagnosis, expensive medicines, and longer time for reimbursements are projected to restrain the market growth. Request Your Free Sample Report of Global C1 Inhibitors Market @ (The free sample of this report is readily available on request). Our Free Sample Report Includes: (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Industry Major Market Players To know an additional revised list of 2020-2021 top market players, request a sample report: Key questions answered in this report: Market Dynamics The C1 inhibitor market can be divided into human-derived and recombinantly derived on the basis of the source. The human-derived C1 inhibitor segment can be further broken down into CINRYZE, Berinert, and HAEGARDA while the recombinant derived segment can be further broken down into Ruconest The C1 inhibitors market can be broken down into intravenous and subcutaneous on the basis of mode of administration. Growing adoption of the subcutaneous route of administration by doctors and improving availability of Ruconest further fuel the C1 inhibitor market. Thus, the subcutaneous mode of administration is likely to exhibit maximum market revenue. Directly Purchase a copy of the report with TOC @ Global C1 Inhibitors Market: Growth Factors High growth in the rise of hereditary angioedema (HAE) and the preferred use of prophylactic treatment will drive the market to higher growth. Additionally, benefits include treatment and prevention of acute attacks and routine prophylaxis against other forms of HAE. Other drivers for the C1 inhibitors market include a rise in awareness by various studies that show the effective nature of C1 inhibitors in the treatment of HAE diseases. The rising requirement for the treatment of HAE diseases coupled with the growing awareness regarding these diseases is all projected to drive the global C1 inhibitors market growth. Growing investments also fuel the market. The rising occurrence of HAE increases the demand for C1 inhibitors, thereby boosting the market during the forecast period. Request Customized Copy of Report @ (We customize your report according to your research need. Ask our sales team for report customization.) North America Is Expected To Flourish During the Forecast Period North America is expected to recoup the largest market share during the forecast period in terms of global revenue collection. Factors pertaining to the rise of the market in the region can be contributed to increased awareness about HAE treatment protocols and widened support for reimbursement support from governmental agencies. Additionally, the well-established healthcare infrastructure and improved healthcare access will also help boost the global C1 inhibitors market in this region. Browse the full “C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at  The global C1 Inhibitors Market can be segmented into: Global C1 Inhibitors Market: By Source Segment Analysis Global C1 Inhibitors Market: By Mode of Administration Segment Analysis Global C1 Inhibitors Market: By End-User Segment  Analysis Key Highlights of this Report: For media inquiry, mail to: sales@fnfresearch.com About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: Follow Us Twitter: Contact Us: Facts & Factors USA: +1-347-989-3985 Email: sales@fnfresearch.com Web: Blog:

NEW YORK, July 31 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. ("Lev") today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its C1 inhibitor, proposed to be marketed as Cinryze(TM), for the acute treatment of hereditary angioedema (HAE). Lev is the first company to submit a licensing application for the acute treatment of HAE in the United States. The FDA has sixty days to determine whether the BLA is sufficiently complete to be filed for substantive review. "Today's filing is an important milestone for Lev and reflects our commitment to provide relief for patients with this rare, debilitating and life-threatening illness," said Joshua D. Schein, Ph.D., Lev's Chief Executive Officer. "We believe CinryzeTM potentially represents a significant advancement in the management of HAE in the U.S. and in improving the lives of patients suffering from this disease." Commenting on the BLA filing, Anthony Castaldo, President, U.S. HAE Association said, "HAE patients in the United States are excited about the prospect of finally having access to C1 inhibitor, a treatment that addresses a tragic and longstanding unmet medical need, and would, if approved, put U.S. HAE patients on par with European HAE patients who have had C1 inhibitor therapy available to them for over three decades." Lev is developing Cinryze(TM) (C1 inhibitor) as a comprehensive replacement therapy for the treatment of HAE, or C1 inhibitor deficiency, a potentially life-threatening genetic disease characterized by recurrent attacks of inflammation. Lev is developing Cinryze(TM) both for the treatment of acute HAE attacks and as a prophylactic therapy to prevent HAE attacks. In March, Lev announced the successful completion of its pivotal Phase III clinical trial for the acute treatment of HAE, in which the protocol-defined primary endpoint was achieved, indicating a clinically and statistically significant reduction in the time to relief of acute HAE symptoms. There is currently no FDA-licensed acute therapy for HAE in the United States. Lev reiterated that top-line results from the prophylactic portion of its Phase III study are expected to be made available during the second half of this year. If positive and supportive, such data may be submitted as an amendment to the BLA to seek an expanded label indication for Cinryze(TM) to include the prevention of HAE attacks. About Hereditary Angioedema HAE is a genetic disorder characterized by recurrent attacks of inflammation affecting the hands, the feet, the face, the abdomen, the urogenital tract and the larynx. The inflammation can be disfiguring, debilitating, or, in the case of laryngeal attacks, life-threatening. HAE is caused by a deficiency of the plasma protein C1 inhibitor. While there is no approved acute therapy for the condition in the United States, replacement therapy with C1 inhibitor has been used to treat HAE in Europe for more than 30 years. There are estimated to be 10,000 people with HAE in the United States. About Lev Pharmaceuticals, Inc. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's C1 inhibitor, proposed to be marketed as CinryzeTM, has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life.threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. For more information about Lev or C1 inhibitor for the treatment of HAE, please contact Lev directly at 212-682-3096, or visit Lev's website at . Additional information on HAE can be obtained from the U.S. Hereditary Angioedema Association at . Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to new information arising out of clinical trial results, our heavy dependence on the success of CinryzeTM, our dependence on our suppliers, our dependence on third parties to manufacture CinryzeTM, obtaining regulatory approval to market CinryzeTM; market acceptance of CinryzeTM, maintaining the orphan drug status associated with CinryzeTM, the risks associated with dependence upon key personnel, and our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the "Risk Factors that May Affect Results" section of our filings with the SEC. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements. Lev Pharmaceuticals, Inc. CONTACT: Jason Tuthill, Director, Investor Relations, of LevPharmaceuticals, Inc., +1-212-850-9130, or jtuthill@levpharma.com Web site: